Video

Immunotherapy Brings 'Radical Change' to Lung Cancer Treatment

Marina Chiara Garassino, M.D., talks about how immunotherapy agents have vastly improved the treatment field of patients with non-small cell lung cancer.

Marina Chiara Garassino, M.D., medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, talks about how immunotherapy agents have vastly improved the treatment field of patients with non-small cell lung cancer.

Over the past few years, there have been exciting advancements with the addition of anti-PD1 and anti-PD-L1 agents to the lung cancer space. Now, even more trials are investigating the use of immunotherapy in both the neoadjuvant and adjuvant settings.

Related Videos
Image of Dr. Goy.
Image of bald man.
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Image of Dr. Salani.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Fakih.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.
Dr. Gabriel A. Brooks discussed the recent FDA product labeling update for Xeloda and 5-FU.